Skip to main content
Funded Studies

Samuil Umansky, MD, PhD, DrSci

President and Chief Scientific Officer at DiamiR, LLC

Location: Monmouth Junction, NJ United States

Samuil Umansky, MD, PhD, DrSci, co-founded DiamiR to develop non-invasive, accurate diagnostic tests for early detection of neurodegenerative diseases. He serves as the chief scientific officer (CSO) and president of the company. Previously, Dr. Umansky co-founded and served as the CSO and President of Xenomics (now TrovaGene, NASDAQ: TROV), served as the CSO of LXR Biotechnology, and was a professor at the Institute of Biological Physics of the USSR Academy of Sciences.

He conducted pioneering studies on DNA degradation during apoptosis. The analysis of cell-free nucleic acids has been a major focus of Dr. Umansky’s research over the last 20 years. Dr. Umansky developed new methods for detection and analysis of small nucleic acids in bodily fluids, and invented transrenal-DNA/RNA technology for prenatal genetic testing, tumor diagnostics and monitoring, transplantation monitoring, and infectious disease diagnostics. He has published over 160 peer-reviewed articles, and is a co-inventor on more than 70 patents and patent applications.

Associated Grants

  • Analysis of Circulating Brain-Enriched microRNA as Biomarkers for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.